Prime Insights

Insights with Impact: more data isn’t better data

Why Prime’s adherence predictors top bulk consumer data. See what new trend is emerging in the pharmacy benefit management industry.

Section divider

    Recent insights

April 26, 2017 

Insights with Impact: Different, but not just to be different

Being different is only better when it makes a difference.

Read about the two studies

April 27, 2017 | Prime Therapeutics

Insights with Impact: Pharmacist interventions

Research proves people do make a difference. Learn about the effects of pharmacist interventions on specific high-risk populations.

Read about two studies

April 6, 2017 | Prime Therapeutics

Prime releases 2017 Drug Trend Reports

Prime is creating partnerships and programs that will reshape the PBM industry. These reports illustrate the powerful results that this work can generate.

Get the highlights

Nov. 11, 2016 | Prime Therapeutics

Managing accelerating autoimmune drugs costs across benefits is critical

Just 5 in every 1,000 members use autoimmune drugs. Yet it’s the most expensive drug class under both the medical and pharmacy benefit — and one of the fastest growing.

Prime's latest autoimmune drug research

Nov. 11, 2016 | Prime Therapeutics

Infographic: Drug pipeline profile: Duchenne muscular dystrophy

New  therapies for this rare disease are in pipeline, and they could have a big impact on drug costs — up to $4.57 per member per year.

DMD and what’s on the horizon

Aug. 31, 2016 | Patrick Gleason, PharmD, FCCP, BCPS

Prime research decodes top Stars-related adherence predictors by category

Prime explores the top predictors of future adherence for three key Star ratings drug categories — high blood pressure, high cholesterol and diabetes — based on a recent study of more than 1.1 million Medicare members.

Top adherence predictors by category

Aug. 24, 2016 | Patrick Gleason, PharmD, FCCP, BCPS

Can big data help boost medicine-related Star ratings?

Prime performs adherence predictive modeling, using big data, to provide evidence-based recommendations to drive higher ratings for Star-related drug categories. 

Top predictors of adherence

Aug. 2 2016 | Jonathan Gavras, MD, FCCP

The CREATES Act: A viable solution for more affordable prescription drug choices

Lawmakers are fighting for more affordable prescription drug choices for families. The CREATES Act can pave the way, and Prime Therapeutics is on board.

How the CREATES Act can help

July 20, 2016 | Cathy Starner, PharmD, BCPS

America’s opioid epidemic: Part 5 — the future of safer opioid use

The opioid crisis is staggering, but steps are being taken in the right direction. What will tomorrow hold for safer opioid use?

Important work being done on the opioid front

Section divider